STOCK TITAN

Avalo Therapeutics (AVTX) Financials

AVTX NASDAQ
FY2025 annual
Revenue $59K -86.6% YoY
Net Income -$78.3M n/m YoY
EPS (Diluted) -$5.84 YoY not available
Operating Cash Flow -$51.5M n/m YoY
Market Cap $387.4M as of Nov 18, 2026
Price / Sales n/m outside the range published as a multiple, on $59K revenue, FY2025
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 0.9x on $436.5M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AVTX SEC filings page.

Avalo Therapeutics, Inc. (AVTX) reported $59K in revenue for fiscal year 2025, down 86.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AVTX FY2025

Avalo's development-led model produced only $59K of FY2025 revenue against $50.1M of research spending and substantial cash use.

Revenue fell 86.6% from FY2024 to FY2025 while research spending rose 105.0%; spending, not sales volume, dictated the operating model. The operating loss still widened from $68.5M to $72.9M, showing that the increased development effort did not yet translate into a smaller annual deficit.

FY2025's net loss was $78.3M versus operating cash outflow of $51.5M, so the accounting loss was not fully matched by current-period operating cash use. The supplied liquidity measure equaled 22.9 months of the latest annual operating outflow, while financing cash flow added $14.6M; reported liquidity therefore reflects funding activity alongside operations, not revenue generation.

Liabilities rose from 11.7% to 28.7% of assets between FY2024 and FY2025, indicating a less equity-dominant balance sheet. Total equity fell 37.6%, yet the current ratio was 8.1x, so short-term coverage remained substantially stronger than the company's operating results.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Avalo Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Altman Z-Score Distress
0.45

Avalo Therapeutics, Inc. scores 0.45, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $448.5M against total assets of $116.5M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
1/7

Avalo Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing
N/A

Avalo Therapeutics, Inc. reported a net loss of $78.3M while operations used $51.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$23.4M
YoYn/m
QoQn/m
5Y CAGRn/m

Avalo Therapeutics, Inc.'s EBITDA was -$23.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$18.9M
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Avalo Therapeutics, Inc. reported a net loss of $18.9M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.34
QoQn/m

Avalo Therapeutics, Inc. earned -$0.34 per diluted share (EPS) in Q3 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt
$65.0M
YoY+141.0%
QoQ-23.9%
5Y CAGR-1.9%
10Y CAGR+22.1%

Avalo Therapeutics, Inc. held $65.0M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
58M
QoQ+7.8%

Avalo Therapeutics, Inc. had 58M shares outstanding in Q3 2026. Against the prior quarter it is up 7.8%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-4.3%
YoY+29.1pp
QoQ+3.8pp

Avalo Therapeutics, Inc.'s quarterly ROE was -4.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 29.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.8 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$15.0M
YoY+10.5%
QoQ-35.8%
5Y CAGR+7.4%

Avalo Therapeutics, Inc. invested $15.0M in research and development in Q3 2026. This represents an increase of 10.5% from the same quarter a year earlier. Against the prior quarter it is down 35.8%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

AVTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AVTX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
RevenueN/AN/AN/AN/A$0-100.0%N/AN/A$192K-66.3%
Cost of RevenueN/AN/AN/AN/AN/A$0-100.0%N/AN/A
R&D Expenses$15.0M+10.5%$23.4M+66.4%$14.0M+54.0%$13.3M+62.1%$13.6M+42.8%$14.1M+205.9%$9.1M+331.1%$8.2M+337.8%
SG&A Expenses$8.4M+49.7%$8.1M+54.5%$6.9M+23.6%$6.5M+24.9%$5.6M+30.1%$5.2M+15.8%$5.5M+73.7%$5.2M+95.7%
Operating Income-$23.4Mn/m-$31.5Mn/m-$20.9Mn/m-$19.7Mn/m-$19.2Mn/m-$19.3Mn/m-$14.7Mn/m-$13.3Mn/m
EBITDA-$23.4Mn/m-$31.5Mn/m-$20.9Mn/m-$19.7Mn/m-$19.1Mn/m-$19.2Mn/m-$14.5Mn/m-$13.2Mn/m
Income Tax$7K-36.4%$18K+12.5%$12K+50.0%$130K+14.0%$11Kn/m$16K+128.6%$8K+14.3%$114Kn/m
Net Income-$18.9Mn/m-$36.4Mn/m-$19.6Mn/m-$13.7Mn/m-$30.6M-232.9%-$20.8M-121.1%-$13.1Mn/m-$35.3Mn/m
EPS (Basic)-$0.34-$0.83-$0.98-$0.37-$2.19-323.5%-$1.92-$1.25-$7.95
EPS (Diluted)-$0.34-$0.83-$0.98-$0.37-$2.19n/m-$1.92-$1.25N/A
Diluted Shares (Avg)55M44M20MN/A14M+29.8%11M11MN/A

Not reported in any period shown, so not listed: Gross Profit, Interest Expense.

AVTX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AVTX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$481.4M+284.8%$490.8M+287.7%$99.9M-27.9%$116.5M-22.7%$125.1M+27.1%$126.6M+16.9%$138.5M+12.0%$150.7M+618.0%
Current Assets$400.7M+252.0%$407.9M+254.2%$88.8M-30.0%$105.3M-24.2%$113.8M+32.2%$115.2M+20.1%$126.9M+14.1%$138.9M+1554.4%
Cash & Equivalents$65.0M+141.0%$85.4M+101.9%$25.0M-80.0%$15.9M-88.2%$27.0M-67.1%$42.3M-54.7%$125.0M+13.5%$134.5M+1714.5%
Short-Term Investments$328.0M+287.4%$314.9M+343.7%$57.0Mn/m$82.5Mn/m$84.7Mn/m$71.0Mn/m$0n/m$0n/m
Long-Term Investments$69.8Mn/m$71.9Mn/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$10.5M0.0%$10.5M0.0%$10.5M0.0%$10.5M0.0%$10.5M0.0%$10.5M0.0%$10.5M0.0%$10.5M0.0%
Total Liabilities$44.9M+33.8%$42.1M+91.4%$31.6M+98.4%$33.4M+88.8%$33.6M-55.7%$22.0M-80.1%$15.9M-92.9%$17.7M+29.3%
Current Liabilities$24.1M+202.2%$21.1M+128.2%$11.6M+106.6%$12.9M+85.9%$8.0M-86.9%$9.3M-90.4%$5.6M-97.4%$7.0M+50.7%
Non-Current Liabilities$20.8M-18.7%$21.0M+64.7%$20.0M+94.0%$20.5M+90.6%$25.6M+70.0%$12.8M-9.3%$10.3M+12.9%$10.7M+18.4%
Total Equity$436.5M+376.9%$448.7M+329.0%$68.3M-44.3%$83.0M-37.6%$91.5M+334.4%$104.6Mn/m$122.6Mn/m$133.0M+1721.4%
Retained Earnings-$523.5Mn/m-$504.5Mn/m-$468.2Mn/m-$448.5Mn/m-$434.8Mn/m-$404.2Mn/m-$383.4Mn/m-$370.3Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.

AVTX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AVTX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$11.5Mn/m-$20.0Mn/m-$17.7Mn/m-$14.2Mn/m-$16.4Mn/m-$11.4Mn/m-$9.5Mn/m-$15.0Mn/m
Depreciation & Amortization$18K-69.5%$17K-87.3%$17K-87.4%$16K-76.5%$59K+73.5%$134K+306.1%$135K+297.1%$68K+58.1%
Stock-Based Compensation$5.2M+65.6%$5.3M+95.2%$3.6M+10.3%N/A$3.2M+70.6%$2.7M+477.1%$3.2M+415.3%N/A
Capital ExpendituresN/AN/AN/AN/AN/AN/AN/A$0n/m
Free Cash FlowN/AN/AN/AN/AN/AN/AN/A-$15.0Mn/m
Investing Cash Flow-$11.2Mn/m-$329.9Mn/m$25.5Mn/m$2.4Mn/m-$13.3Mn/m-$70.9Mn/m$0-100.0%$0n/m
Financing Cash Flow$2.5M-82.3%$410.2Mn/m$1.4Mn/m$687K-99.0%$14.4Mn/m-$469Kn/m$0-100.0%$67.7M+6770800.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

AVTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AVTX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating MarginN/AN/AN/AN/AN/AN/AN/A-6931.8%
Net MarginN/AN/AN/AN/AN/AN/AN/A-18405.7%
Return on Equity-4.3%+29.1pp-8.1%+11.8pp-28.7%-18.0pp-16.5%+10.0pp-33.5%-142.8pp-19.9%-10.7%-26.6%+85.3pp
Return on Assets-3.9%+20.5pp-7.4%+9.0pp-19.7%-10.2pp-11.8%+11.7pp-24.5%-47.9pp-16.4%-107.3pp-9.5%+88.5pp-23.4%+15.5pp
Current Ratio16.63+2.4x19.31+6.9x7.66-14.9x8.14-11.8x14.28+12.9x12.44+11.4x22.61+22.1x19.96+18.1x
Liabilities-to-Equity0.10-0.3x0.09-0.1x0.46+0.3x0.40+0.3x0.37-3.2x0.210.130.13-1.7x
Asset TurnoverN/AN/AN/AN/A0.000.0xN/AN/A0.000.0x
FCF MarginN/AN/AN/AN/AN/AN/AN/A-7835.4%

Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Avalo Therapeutics, Inc. AVTX FY2025 $59K -$78.3M N/A $387.4M —
Shattuck Labs, Inc. STTK FY2025 $1.0M -$48.8M N/A $455.2M 61/100
Assembly Biosciences, Inc ASMB FY2025 $72.3M -$6.1M -8.5% $458.5M 87/100
Gyre Therapeutics, Inc. GYRE FY2025 $116.6M $9.9M 8.5% $475.0M 36/100
Arvinas, Inc ARVN FY2025 $262.6M -$80.8M -30.8% $443.0M 77/100
CytomX Therapeutics, Inc. CTMX FY2025 $76.2M -$17.4M -22.8% $409.8M 50/100

Frequently Asked Questions

Avalo Therapeutics, Inc. (AVTX) reported $59K in total revenue for fiscal year 2025. This represents a -86.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Avalo Therapeutics, Inc. (AVTX) revenue declined by 86.6% year-over-year, from $441K to $59K in fiscal year 2025.

No, Avalo Therapeutics, Inc. (AVTX) reported a net loss of $78.3M in fiscal year 2025.

Avalo Therapeutics, Inc. (AVTX) reported diluted earnings per share of -$5.84 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Avalo Therapeutics, Inc. (AVTX) had EBITDA of -$72.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Avalo Therapeutics, Inc. (AVTX) has a return on equity of -94.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Avalo Therapeutics, Inc. (AVTX) recorded an outflow of $51.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Avalo Therapeutics, Inc. (AVTX) had $116.5M in total assets as of fiscal year 2025, including both current and long-term assets.

Avalo Therapeutics, Inc. (AVTX) invested $50.1M in research and development during fiscal year 2025.

Avalo Therapeutics, Inc. (AVTX) had 23M shares outstanding as of fiscal year 2025.

Avalo Therapeutics, Inc. (AVTX) had a current ratio of 8.14 as of fiscal year 2025, which is generally considered healthy.

Avalo Therapeutics, Inc. (AVTX) had a liabilities-to-equity ratio of 0.40 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Avalo Therapeutics, Inc. (AVTX) had a return on assets of -67.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Avalo Therapeutics, Inc. (AVTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $387.4M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Avalo Therapeutics, Inc. (AVTX) has no price-to-sales ratio at the moment: outside the range published as a multiple (on $59K revenue, FY2025). The market capitalization is $387.4M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Avalo Therapeutics, Inc. (AVTX) held $98.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $51.5M over that year. Dividing the one by the other, the reported balance equals about 23 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Avalo Therapeutics, Inc. (AVTX) has an Altman Z-Score of 0.45, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Avalo Therapeutics, Inc. (AVTX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Avalo Therapeutics, Inc. (AVTX) reported a net loss of $78.3M while operations used $51.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top